These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 22933513)

  • 1. An update on the use of ambrisentan in pulmonary arterial hypertension.
    D'Alto M
    Ther Adv Respir Dis; 2012 Dec; 6(6):331-43. PubMed ID: 22933513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy evaluation of ambrisentan in pulmonary hypertension.
    Vizza CD; Fedele F; Pezzuto B; Rubin LJ
    Expert Opin Drug Saf; 2012 Nov; 11(6):1003-11. PubMed ID: 22861496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ambrisentan, an endothelin receptor type A-selective endothelin receptor antagonist, for the treatment of pulmonary arterial hypertension.
    Kingman M; Ruggiero R; Torres F
    Expert Opin Pharmacother; 2009 Aug; 10(11):1847-58. PubMed ID: 19601701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of ambrisentan in the management of pulmonary hypertension.
    Hrometz SL; Shields KM
    Ann Pharmacother; 2008 Nov; 42(11):1653-9. PubMed ID: 18957622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic response (ATHENA-1).
    Shapiro S; Torres F; Feldman J; Keogh A; Allard M; Blair C; Gillies H; Tislow J; Oudiz RJ
    Respir Med; 2017 May; 126():84-92. PubMed ID: 28427554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of pulmonary arterial hypertension: role of ambrisentan.
    Barst RJ
    Vasc Health Risk Manag; 2007; 3(1):11-22. PubMed ID: 17583171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.
    Galiè N; Olschewski H; Oudiz RJ; Torres F; Frost A; Ghofrani HA; Badesch DB; McGoon MD; McLaughlin VV; Roecker EB; Gerber MJ; Dufton C; Wiens BL; Rubin LJ;
    Circulation; 2008 Jun; 117(23):3010-9. PubMed ID: 18506008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ambrisentan: a review of its use in pulmonary arterial hypertension.
    Rivera-Lebron BN; Risbano MG
    Ther Adv Respir Dis; 2017 Jun; 11(6):233-244. PubMed ID: 28425346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endothelin receptor antagonists for the treatment of pulmonary artery hypertension.
    Rubin LJ
    Life Sci; 2012 Oct; 91(13-14):517-21. PubMed ID: 22884806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ambrisentan.
    Frampton JE
    Am J Cardiovasc Drugs; 2011 Aug; 11(4):215-26. PubMed ID: 21623643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities.
    McGoon MD; Frost AE; Oudiz RJ; Badesch DB; Galie N; Olschewski H; McLaughlin VV; Gerber MJ; Dufton C; Despain DJ; Rubin LJ
    Chest; 2009 Jan; 135(1):122-129. PubMed ID: 18812445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemodynamic stability after transitioning between endothelin receptor antagonists in patients with pulmonary arterial hypertension.
    Fox B; Langleben D; Hirsch AM; Schlesinger RD; Eisenberg MJ; Joyal D; Blenkhorn F; Lesenko L
    Can J Cardiol; 2013 Jun; 29(6):672-7. PubMed ID: 22819360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brief report: effect of ambrisentan treatment on exercise-induced pulmonary hypertension in systemic sclerosis: a prospective single-center, open-label pilot study.
    Saggar R; Khanna D; Shapiro S; Furst DE; Maranian P; Clements P; Abtin F; Dua S; Belperio J; Saggar R
    Arthritis Rheum; 2012 Dec; 64(12):4072-7. PubMed ID: 22777623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic evaluation of ambrisentan.
    Buckley MS; Wicks LM; Staib RL; Kirejczyk AK; Varker AS; Gibson JJ; Feldman JP
    Expert Opin Drug Metab Toxicol; 2011 Mar; 7(3):371-80. PubMed ID: 21299444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative safety and tolerability of endothelin receptor antagonists in pulmonary arterial hypertension.
    Aversa M; Porter S; Granton J
    Drug Saf; 2015 May; 38(5):419-35. PubMed ID: 25792028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ambrisentan for the management of pulmonary arterial hypertension.
    Cheng JW
    Clin Ther; 2008 May; 30(5):825-33. PubMed ID: 18555930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ambrisentan and its role in the management of pulmonary arterial hypertension.
    Macintyre IM; Dhaun N; Goddard J; Webb DJ
    Drugs Today (Barc); 2008 Dec; 44(12):875-85. PubMed ID: 19198697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ambrisentan.
    Croxtall JD; Keam SJ
    Drugs; 2008; 68(15):2195-204. PubMed ID: 18840007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma.
    Kabunga P; Coghlan G
    Drugs; 2008; 68(12):1635-45. PubMed ID: 18681488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis.
    Dranitsaris G; Mehta S
    Appl Health Econ Health Policy; 2009; 7(1):43-59. PubMed ID: 19558194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.